Cargando…

Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial

IMPORTANCE: There is a critical need for careful and independent validation of reported symptomatic efficacy and dopaminergic biomarker changes induced by nilotinib in Parkinson disease (PD). OBJECTIVES: To assess safety and tolerability of nilotinib in participants with moderately advanced PD. Seco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simuni, Tanya, Fiske, Brian, Merchant, Kalpana, Coffey, Christopher S., Klingner, Elizabeth, Caspell-Garcia, Chelsea, Lafontant, David-Erick, Matthews, Helen, Wyse, Richard K., Brundin, Patrik, Simon, David K., Schwarzschild, Michael, Weiner, David, Adams, Jamie, Venuto, Charles, Dawson, Ted M., Baker, Liana, Kostrzebski, Melissa, Ward, Tina, Rafaloff, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737147/ https://www.ncbi.nlm.nih.gov/pubmed/33315105 http://dx.doi.org/10.1001/jamaneurol.2020.4725

Ejemplares similares

Nilotinib – Differentiating the Hope from the Hype
por: Wyse, Richard K., et al.
Publicado: (2016)

Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older
por: Brumm, Michael C., et al.
Publicado: (2023)

Linked Clinical Trials – The Development of New Clinical Learning Studies in Parkinson’s Disease Using Screening of Multiple Prospective New Treatments
por: Brundin, Patrik, et al.
Publicado: (2013)

Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?
por: Schwarzschild, Michael A.
Publicado: (2017)

Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease
por: Picillo, Marina, et al.
Publicado: (2022)

High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease
por: Russo, Marco J., et al.
Publicado: (2021)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update
por: McFarthing, Kevin, et al.
Publicado: (2023)

Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2022)

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease
por: Simuni, Tanya, et al.
Publicado: (2016)

The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease
por: Karuppagounder, Senthilkumar S., et al.
Publicado: (2014)

Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
por: Stott, Simon R. W., et al.
Publicado: (2021)

Correction to: High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease
por: Russo, Marco J., et al.
Publicado: (2021)

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
por: Merchant, Kalpana M., et al.
Publicado: (2023)

Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease
por: Venuto, Charles S., et al.
Publicado: (2021)

Nilotinib-Associated Destructive Thyroiditis
por: Bakerywala, Suhalia, et al.
Publicado: (2015)

Nilotinib-Induced Keratosis Pilaris
por: Leong, Wai Mun Sean, et al.
Publicado: (2016)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

A Case of Severe, Nilotinib-Induced Liver Injury
por: Belopolsky, Yuliya, et al.
Publicado: (2019)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
por: DeRemer, David L, et al.
Publicado: (2011)

Parkinson Matters
por: Darweesh, Sirwan K.L., et al.
Publicado: (2018)

Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study
por: Weintraub, Daniel, et al.
Publicado: (2023)

Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
por: Brumm, Michael C., et al.
Publicado: (2023)

Nilotinib based pharmacophore models for BCRABL
por: Sabitha, Kesavan
Publicado: (2012)

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
por: Hochhaus, Andreas, et al.
Publicado: (2015)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update
por: McFarthing, Kevin, et al.
Publicado: (2021)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
por: McFarthing, Kevin, et al.
Publicado: (2020)

Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures
por: Chahine, Lana M., et al.
Publicado: (2019)

Effects of nilotinib on regulatory T cells: the dose matters
por: Fei, Fei, et al.
Publicado: (2010)

Nilotinib-induced Perforating Folliculitis: Two Cases
por: Saraswat, Neerja, et al.
Publicado: (2018)

Nilotinib: QTc prolongation: 2 case reports
Publicado: (2021)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Waiting for PARIS—A Biological Target in Search of a Drug: PARIS farnesylation: Considerations in addressing a new biological target for neuroprotection in patients with Parkinson’s disease
por: Wyse, Richard K., et al.
Publicado: (2022)

A Proposed Roadmap for Parkinson’s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein
por: Merchant, Kalpana M., et al.
Publicado: (2019)

Proposal for a Biologic Staging System of Parkinson’s Disease
por: Chahine, Lana M., et al.
Publicado: (2023)

Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib
por: Sanford, David, et al.
Publicado: (2014)

Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
por: Weintraub, Daniel, et al.
Publicado: (2020)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update
por: McFarthing, Kevin, et al.
Publicado: (2022)

Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder
por: Chahine, Lana M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vjl1g8glsefe372khsn6bnbc31